AUIC - A general target for the optimization of dosing regimens of antibiotics?

Annals of Pharmacotherapy

Volumn 30, Issue 9, 1996, Pages 1024-1028

  Costa, Teresa Dalla ^a   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFMENOXIME; CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; COMPARTMENT MODEL; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG HALF LIFE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

EID: 0029793239     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000919     Document Type: Article

References (6)

1. Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP Ann Pharmacother 1991;25:1050-7.
2. Flaherty JF, Rodondi LC, Guglielmo BJ, Fleishaker JC, Townsend RJ, Gambertoglio JG. Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens. Antimicrob Agents Chemother 1988;32:1825-9.
3. Ebert SC. Pharmacokinetic-pharmacodynamic modeling of irreversible drug effects. In: Derendorf H, Hochhaus G, eds. Handbook of pharmacokinetic-pharmacodynamic correlation. Boca Raton, FL: CRC Press, 1995:35-56.
4. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993;37:483-90.
5. Amsden GW, Ballow CH, Schentag JJ. Population pharmacokinetic methods to optimize antibiotic effects. Drug Invest 1993;5:256-68.
6. Nightingale CH, Quintiliani R, Nicolau DP. Intelligent dosing of antimicrobials. Curr Clin Top Infect Dis 1994;14:252-65.